NewAmsterdam Pharma (NASDAQ:NAMSW) Short Interest Up 66.3% in April

NewAmsterdam Pharma (NASDAQ:NAMSW) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 13,300 shares, an increase of 66.3% from the March 31st total of 8,000 shares. Based on an average daily trading volume, of 12,500 shares, the short-interest ratio is currently 1.1 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NewAmsterdam Pharma stock. ADAR1 Capital Management LLC acquired a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 82,857 shares of the company’s stock, valued at approximately $259,000.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ NAMSW traded up $0.10 during midday trading on Monday, hitting $9.73. The stock had a trading volume of 200 shares, compared to its average volume of 16,534. The company has a fifty day moving average price of $10.44 and a 200 day moving average price of $6.36. NewAmsterdam Pharma has a 1-year low of $0.99 and a 1-year high of $14.67.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.